97 related articles for article (PubMed ID: 9658376)
1. A novel in vitro model to screen steroid 5 alpha-reductase inhibitors against benign prostatic hyperplasia.
Sun ZY; Tu ZH
Methods Find Exp Clin Pharmacol; 1998 May; 20(4):283-7. PubMed ID: 9658376
[TBL] [Abstract][Full Text] [Related]
2. 5 alpha-reductase inhibition by a new synthetic steroid (PM-9) in cultures of Penicillium crustosum.
Cabeza M; Quiroz A; Bratoeff E; García G; Ramírez E; Flores E
Proc West Pharmacol Soc; 2002; 45():164-5. PubMed ID: 12434569
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetic analysis of human steroid 5 alpha reductase type II: comparison of finasteride and dutasteride.
Makridakis N; Reichardt JK
J Mol Endocrinol; 2005 Jun; 34(3):617-23. PubMed ID: 15956333
[TBL] [Abstract][Full Text] [Related]
4. Selectivity of finasteride as an in vivo inhibitor of 5alpha-reductase isozyme enzymatic activity in the human prostate.
Span PN; Völler MC; Smals AG; Sweep FG; Schalken JA; Feneley MR; Kirby RS
J Urol; 1999 Jan; 161(1):332-7. PubMed ID: 10037433
[TBL] [Abstract][Full Text] [Related]
5. Z-350, a novel compound with alpha 1-adrenoceptor antagonistic and steroid 5 alpha-reductase inhibitory actions: pharmacological properties in vivo.
Fukuta Y; Fukuda Y; Higashino R; Yoshida K; Ogishima M; Tamaki H; Takei M
J Pharmacol Exp Ther; 1999 Sep; 290(3):1013-8. PubMed ID: 10454472
[TBL] [Abstract][Full Text] [Related]
6. A model for the turnover of dihydrotestosterone in the presence of the irreversible 5 alpha-reductase inhibitors GI198745 and finasteride.
Gisleskog PO; Hermann D; Hammarlund-Udenaes M; Karlsson MO
Clin Pharmacol Ther; 1998 Dec; 64(6):636-47. PubMed ID: 9871428
[TBL] [Abstract][Full Text] [Related]
7. 5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction.
Rittmaster RS
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):389-402. PubMed ID: 18471794
[TBL] [Abstract][Full Text] [Related]
8. [Establishment of an in vitro screening model for steroid 5 alpha-reductase inhibitors with the microplate reader].
Wu JH; Sun ZY
Zhonghua Nan Ke Xue; 2013 Jun; 19(6):483-6. PubMed ID: 23862223
[TBL] [Abstract][Full Text] [Related]
9. Self organizing molecular field analysis on a series of human 5alpha-reductase inhibitors: unsaturated 3-carboxysteroid.
Thareja S; Aggarwal S; Bhardwaj TR; Kumar M
Eur J Med Chem; 2009 Dec; 44(12):4920-5. PubMed ID: 19716209
[TBL] [Abstract][Full Text] [Related]
10. Prostates, pates, and pimples. The potential medical uses of steroid 5 alpha-reductase inhibitors.
Tenover JS
Endocrinol Metab Clin North Am; 1991 Dec; 20(4):893-909. PubMed ID: 1723383
[TBL] [Abstract][Full Text] [Related]
11. [Enzyme inhibition in the drug therapy of benign prostatic hyperplasia].
Drsata J
Cas Lek Cesk; 2002 Oct; 141(20):630-5. PubMed ID: 12515038
[TBL] [Abstract][Full Text] [Related]
12. 19-nor-10-azasteroids: a novel class of inhibitors for human steroid 5alpha-reductases 1 and 2.
Guarna A; Belle C; Machetti F; Occhiato EG; Payne AH; Cassiani C; Comerci A; Danza G; De Bellis A; Dini S; Marrucci A; Serio M
J Med Chem; 1997 Mar; 40(7):1112-29. PubMed ID: 9089333
[TBL] [Abstract][Full Text] [Related]
13. [Effect of dutasteride on reduction of plasma DHT following finasteride therapy in patients with benign prostatic hyperplasia].
Botto H; Lan O; Poulain JE; Comenducci A
Prog Urol; 2005 Dec; 15(6):1090-5. PubMed ID: 16429658
[TBL] [Abstract][Full Text] [Related]
14. Drug Insight: 5alpha-reductase inhibitors for the treatment of benign prostatic hyperplasia.
Marberger M
Nat Clin Pract Urol; 2006 Sep; 3(9):495-503. PubMed ID: 16964191
[TBL] [Abstract][Full Text] [Related]
15. Effect of finasteride (Proscar MSD) on seminal composition, prostate function and fertility in male dogs.
Iguer-Ouada M; Verstegen JP
J Reprod Fertil Suppl; 1997; 51():139-49. PubMed ID: 9404280
[TBL] [Abstract][Full Text] [Related]
16. Kinetic analysis of 5 alpha-reductase isoenzymes in benign prostatic hyperplasia (BPH).
Rennie PS; Bruchovsky N; McLoughlin MG; Batzold FH; Dunstan-Adams EE
J Steroid Biochem; 1983 Jul; 19(1A):169-73. PubMed ID: 6193340
[TBL] [Abstract][Full Text] [Related]
17. 5alpha-reductase inhibitors.
Rittmaster RS
J Androl; 1997; 18(6):582-7. PubMed ID: 9432130
[No Abstract] [Full Text] [Related]
18. Structure-activity relationship for inhibition of 5alpha-reductase by triterpenoids isolated from Ganoderma lucidum.
Liu J; Kurashiki K; Shimizu K; Kondo R
Bioorg Med Chem; 2006 Dec; 14(24):8654-60. PubMed ID: 16962782
[TBL] [Abstract][Full Text] [Related]
19. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
[TBL] [Abstract][Full Text] [Related]
20. 5alpha-Reductase inhibitor treatment of prostatic diseases: background and practical implications.
Dörsam J; Altwein J
Prostate Cancer Prostatic Dis; 2009; 12(2):130-6. PubMed ID: 19030020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
